Oncocyte to Participate in Upcoming Investor Events

Rhea-AI Summary

Oncocyte Corporation (Nasdaq: OCX) announced participation in two key investor conferences. The UBS Genomics 2.0 & MedTech Innovations Summit will take place on August 12, 2021, at Montage Laguna Beach, featuring 1x1 and group meetings. Following this, the 6th Annual Needham Virtual Med Tech & Diagnostics Conference is scheduled for August 17, 2021, also with 1x1 and group formats. Oncocyte aims to enhance cancer diagnosis and treatment through its precision diagnostics and proprietary tests, including DetermaRx and DetermaIO, which are designed to improve patient outcomes.

IRVINE, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced that management will participate at two upcoming investor conferences.

Conference Details:

UBS Genomics 2.0 & MedTech Innovations Summit
Date: Thursday, August 12, 2021
Location: Montage Laguna Beach
Format: 1x1 and Group Investor Meetings

6^th Annual Needham Virtual Med Tech & Diagnostics Conference
Date: Tuesday, August 17, 2021
Format: 1x1 and Group Investor Meetings

Investors interested in meeting with the Oncocyte Management team during these events should contact their respective UBS or Needham representatives.

About Oncocyte Corporation
Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage of care. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research tool in drug development, assesses the tumor microenvironment to predict response to immunotherapies. The Company’s robust pipeline of future tests also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.

DetermaRx, DetermaIO, DetermaTx, DetermaCNI and DetermaMx are trademarks of Oncocyte Corporation.

Investor Contact
Bob Yedid
LifeSci Advisors, LLC
646-597-6989
bob@lifesciadvisors.com

FAQ

What are the dates for the upcoming investor conferences involving Oncocyte (OCX)?

Oncocyte will participate in the UBS Genomics 2.0 & MedTech Innovations Summit on August 12, 2021, and the 6th Annual Needham Virtual Med Tech & Diagnostics Conference on August 17, 2021.

Where is the UBS conference being held for Oncocyte (OCX)?

The UBS Genomics 2.0 & MedTech Innovations Summit will be held at Montage Laguna Beach.

What is the purpose of Oncocyte's participation in these conferences?

Oncocyte aims to engage with investors and provide insights into its precision diagnostics efforts in cancer treatment.

What proprietary tests does Oncocyte (OCX) offer?

Oncocyte offers tests such as DetermaRx, DetermaIO, and several others aimed at improving cancer diagnosis and treatment.

How can investors contact Oncocyte for meetings during the conferences?

Investors interested in meetings during the events should contact their respective UBS or Needham representatives.